FINNENCE ▪ THE WIRE FILE
THE WIRE · № 57253
Company■ Unclear/unknown
New Phase 3 trial: ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease — Boehringer Ingelheim
KINDCompany
DIRECTION■ Unclear/unknown
SOURCES2
ENTITIES1
STORY SIZE2 RECORDS
FIRST SEEN2026-09-30 12:00 UTC
LAST UPDATE2026-09-30 12:00 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
ELEVATE-LIVER tests survodutide for heart and liver outcomes in obesity, extending the drug's potential indications.
Survodutide expands into liver outcomes
CATALYST TO WATCH
Trial enrollment and data
MAIN RISK
Not yet recruiting, high failure risk
FULL DISPATCH
Sponsor: Boehringer Ingelheim; Status: Not Yet Recruiting; Conditions: Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease; Interventions: Survodutide, Placebo matching survodutide; Enrollment: 600 (estimated); First posted: 2026-09-30; NCT: NCT07850063
02 THE STORY SO FAR
THE RECORD, IN ORDER.
UPDATED 2 TIMES · FIRST 2026-09-30 12:00 UTC · LAST 2026-09-30 12:00 UTC2026-09-30 12:00 UTCCompanyNew Phase 3 trial: ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease — Boehringer IngelheimCURRENT RECORD
2026-09-30 12:00 UTCCompanyNew Phase 3 trial: SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight — Boehringer Ingelheim
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
New Phase 3 trial: SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight — Boehringer Ingelheim2026-09-30 12:00 UTC
New Phase 3 trial: SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight — Boehringer Ingelheim2026-09-30 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: Study of PK and Safety of the LicartTM Topical System in Pediatric and Adult Participants With Minor Soft Tissue Injury — IBSA Institut Biochimique SA2026-09-30 12:00 UTC
Phase 3 results posted: Study of PK and Safety of the LicartTM Topical System in Pediatric and Adult Participants With Minor Soft Tissue Injury — IBSA Institut Biochimique SA2026-09-30 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy — Teva Pharmaceuticals USA2026-09-30 12:00 UTC
Phase 3 results posted: Study Comparing Estradiol Vaginal Inserts 4mcg To IMVEXXY ® (Estradiol Vaginal Inerts 4 mcg) In The Treatment Of Dyspareunia in Women With Vulvur and Vaginal Atrophy — Teva Pharmaceuticals USA2026-09-30 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases — Takeda2026-09-30 12:00 UTC
Phase 3 results posted: A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases — Takeda2026-09-30 12:00 UTC
→CORRELATIONshares Healthcare
New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis2026-09-30 12:03 UTC
New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis2026-09-30 12:03 UTC
→CORRELATIONshares Healthcare
HealthPartners and Essentia Health Propose Major Merger2026-09-30 12:56 UTC
HealthPartners and Essentia Health Propose Major Merger2026-09-30 12:56 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.